Screening for colon cancer requires preparation in the form of consumption of a large volume (usually at least 4 L) of polyethylene glycol (golytely) to clear the colon of stool and debris. Patients usually find this process to be unpleasant, and also experience pain, discomfort, and cramping on the ensuing colonoscopy procedure. Those who are at high risk, such as history of ulcerative colitis, Crohn's disease, and familial syndromes are required to undergo a colonoscopy annually. Methods that can accurately assess the colon for the presence of colonic dysplasia in this population may reduce the frequency or extend the interval in between these procedures, thus saving time, cost, and patient inconvenience. The development of novel techniques for in vivo molecular and cellular imaging in the pre-clinical and clinical setting, particularly those that have molecular specificity for neoplastic antigens, could have significant implications for the detection of neoplasia in the colon, identification of malignancy recurrence and monitoring of therapeutic response. The increased availability of clinical SPECT/CT and PET/CT scanners can facilitate the translation of new tumor imaging radioligands to the clinic. The successful outcome of this Project will provide new tools that should lead to important pre-clinical opportunities to further understand the biology and treatment response of genetically engineered models of this disease. Successful validation of these novel reporter probes will provide for new clinical diagnostic imaging capabilities that may lead to improved patient care by assessing those at high risk for the appropriate timing of colonoscopy procedures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA136429-05
Application #
8381390
Study Section
Special Emphasis Panel (ZCA1-SRRB-9)
Project Start
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$63,599
Indirect Cost
$20,230
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Joshi, Bishnu P; Duan, Xiyu; Kwon, Richard S et al. (2016) Multimodal endoscope can quantify wide-field fluorescence detection of Barrett's neoplasia. Endoscopy 48:A1-A13
Joshi, Bishnu P; Pant, Asha; Duan, Xiyu et al. (2016) Multimodal Video Colonoscope for Targeted Wide-Field Detection of Nonpolypoid Colorectal Neoplasia. Gastroenterology 150:1084-6
Zhou, Juan; Joshi, Bishnu P; Duan, Xiyu et al. (2015) EGFR Overexpressed in Colonic Neoplasia Can be Detected on Wide-Field Endoscopic Imaging. Clin Transl Gastroenterol 6:e101
Khondee, Supang; Rabinsky, Emily F; Owens, Scott R et al. (2015) Targeted therapy of colorectal neoplasia with rapamycin in peptide-labeled pegylated octadecyl lithocholate micelles. J Control Release 199:114-21
Atreya, Raja; Neumann, Helmut; Neufert, Clemens et al. (2014) In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med 20:313-8
Qiu, Zhen; Khondee, Supang; Duan, Xiyu et al. (2014) Vertical cross-sectional imaging of colonic dysplasia in vivo with multi-spectral dual axes confocal endomicroscopy. Gastroenterology 146:615-7
Khondee, Supang; Wang, Thomas D (2013) Progress in molecular imaging in endoscopy and endomicroscopy for cancer imaging. J Healthc Eng 4:1-22
Liu, Zhongyao; Miller, Sharon J; Joshi, Bishnu P et al. (2013) In vivo targeting of colonic dysplasia on fluorescence endoscopy with near-infrared octapeptide. Gut 62:395-403
Sturm, Matthew B; Joshi, Bishnu P; Lu, Shaoying et al. (2013) Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results. Sci Transl Med 5:184ra61
Sevick-Muraca, Eva M; Akers, Walter J; Joshi, Bishnu P et al. (2013) Advancing the translation of optical imaging agents for clinical imaging. Biomed Opt Express 4:160-70

Showing the most recent 10 out of 35 publications